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Clinical applicability of non-invasive markers
for liver ﬁbrosis in chronic hepatitis CTo the Editor:
We fully agree with Sebastiani et al. [1] regarding the
need for a rationale approach to implement non-inva-
sive tests of liver ﬁbrosis in clinical practice. We recently
showed that available biological tests, from the simplest
APRI to the most sophisticated Fibrotest or Fibrome-
ter, had global diagnostic performances similar to each
other with AUROC around 0.80 for the diagnosis of sig-
niﬁcant ﬁbrosis [2]. These tests are clearly not accurate
enough to precisely stage liver ﬁbrosis in all cases [3].
However, they may give important clues on ﬁbrosis
especially when used in combination. Two algorithms
have been recently proposed by Sebastiani et al. [4]
and by our team [2] in order to reliably assess ﬁbrosis
stages without the need for a liver biopsy. Interestingly,
both algorithms combine the same tests, namely, APRI
and Fibrotest, which have been found to be statistically
independent. In the study presented here, Sebastiani
et al. [1] compared the performance of these algorithms
and found that both attained very good accuracy, with a
greater reduction of liver biopsies by using their
algorithm.
These important results give rise to several com-
ments. Sebastiani’s algorithm is sequential and utilises
as ﬁrst line the cost free APRI. Such a sequential ap-
proach is pragmatic since this test is virtually always
available at the time patients are referred for chronic
hepatitis C. At this stage physicians must be aware that
this test can be coupled with simple laboratory tests that
perform well in terms of ﬁbrosis prediction, as recently
reported by Nahon et al. [5]. At this step the ﬁrst clinical
question asked by both algorithms is ‘‘can one exclude
signiﬁcant ﬁbrosis, i.e. ﬁbrosis stage greater than F1
?”. This question is crucial since patients with no or mild
ﬁbrosis must be reasssured and antiviral treatment can
be delayed. At this stage, underestimation of liver ﬁbro-
sis may have a strong detrimental impact on clinical
management and the use of non-invasive tests with
excellent negative predictive value (NPV) is mandatory.
In Sebastiani’s algorithm this diﬃculty is overcome by
performing a liver biopsy in all patients with APRI be-0168-8278/$34.00  2008 Published by Elsevier B.V. on behalf of the Europ
doi:10.1016/j.jhep.2008.01.018low 0.5 and in patients with APRI ranging from 0.5 to
1.5 and Fibrotest lower than 0.32. In our published ser-
ies of 188 patients in which the percentage of F0F1
stages was higher than that of Sebastiani (49% versus
30%), these criteria were met in 51% of patients. These
data mean that by using Sebastiani’s algorithm a
substantial number of biopsies would be performed in
patients with the less severe ﬁbrosis stage. In our algo-
rithm, the use of more stringent cut-oﬀs (APRI < 0.5
and Fibrotest < 0.22) allowed to select a small propor-
tion (13%) of patients in whom signiﬁcant ﬁbrosis could
be excluded with more than 90% certainty. Such accu-
racy seems to us reasonable to wave liver biopsy in this
situation, especially when the clinical setting is consis-
tent with a mild disease.
Following Sebastiani’s algorithm, patients with
APRI greater than 1.5 or with APRI ranging from 0.5
to 1.5 and Fibrotest > 0.32 are expected to have signiﬁ-
cant ﬁbrosis with an excellent positive predictive value
(PPV). In our series, we conﬁrmed these results although
the PPV was slightly lower (76%) due again to the lower
prevalence of stages F2F3F4 in our population. We
agree that such accuracy is suﬃcient to make the deci-
sion of antiviral therapy at least in naı¨ve patients with-
out severe co-morbidities. However, a major clinical
question remains to be answered at this step, which is
‘‘can one exclude the presence of cirrhosis ?”. This point
is also crucial since cirrhotic patients must have speciﬁc
management including screening for liver failure, portal
hypertension and hepato-cellular carcinoma. For these
reasons, Sebastiani et al. [4] described a second algo-
rithm for the diagnosis of cirrhosis that logically should
be applied to all patients classiﬁed as having signiﬁcant
ﬁbrosis. In this algorithm, patients with APRI greater
than 0.5 and Fibrotest F2F3 should proceed to undergo-
ing a liver biopsy. In our series, applying sequentially
both Sebastiani’s algorithms the liver biopsy would have
been eventually avoided in only 11% of patients. In our
algorithm, we have chosen stringent cut-oﬀs for APRI
(2.0) and Fibrotest (0.59) that allowed the diagnosis of
extensive ﬁbrosis in 20% of patients with excellentean Association for the Study of the Liver.
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Fig. 1. Pragmatic algorithm for the use of non-invasive tests. (1) APRI < 0.5 and Fibrotest < 0.22, or any combination with NPV close to 100%. (2)
APRI < 1.5 and Fibrotest < 0.46, or Fibrometer excluding F3F4, or Fibroscan < 11.7 KPa. (3) Clinical examination + US, Fibrometer giving F4,
APRI > 2 and Fibrotest > 0.59 or any combination PPV close to 100%.
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could also help in the diagnosis of cirrhosis [6]. In our
algorithm, patients in the grey zone in whom neither
F0F1 nor F3F4 can be aﬃrmed are oﬀered a liver
biopsy. As highlighted by Sebastiani et al. [1] these crite-
ria are met by the majority (67% in our study) of pa-
tients, explaining the low number of avoided biopsies
in our algorithm. Another option would be to choose
other cut-oﬀs in order to accurately exclude cirrhosis
in patients suspected of having signiﬁcant ﬁbrosis. We
thus performed a new statistical analysis showing that
cirrhosis could be ruled out in patients with APRI < 1.5
and FT < 0.46 with 100% certainty, such a situation
being met in 59% of patients. In this setting, other
non-invasive tests such as Fibrometer and Fibroscan ap-
pear to be also very accurate to exclude cirrhosis [7,8]. In
this situation, non-invasive tests allow the selection of
patients at high risk of signiﬁcant ﬁbrosis but without
cirrhosis, who can be eligible for antiviral treatment
even without an accurate knowledge of the stage of
ﬁbrosis (Fig. 1).
In conclusion, we fully agree with Sebastiani et al.
regarding the respective role of non-invasive tests and li-
ver biopsy. Non-invasive tests should not be considered
as tools aiming at replacing liver biopsy – they do not
give the same information – but in some cases they
may render the biopsy unnecessary to make the right
clinical decision. An increasing number of non-invasive
tests and algorithms are becoming available. As we are
waiting for further studies that will compare them toone another in the future, we present here a pragmatic
attitude that seems to us rational and applicable in daily
clinical practice.
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